A carregar...
Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells
Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment for prostate cancers. Due to high side effects of monotherapy, however, combinations with novel adjuvants have emerged as an alternative strategy in cancer therapy protocols. Here, we inve...
Na minha lista:
| Publicado no: | Asian Pac J Cancer Prev |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
West Asia Organization for Cancer Prevention
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5454715/ https://ncbi.nlm.nih.gov/pubmed/28032735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/APJCP.2016.17.11.5031 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|